Ketosis may promote brain macroautophagy by activating Sirt1 and hypoxia-inducible factor-1

Medical Hypotheses

Volumn 85, Issue 5, 2015, Pages 631-639

  McCarty, Mark F ^a   DiNicolantonio, James J ^b   O'Keefe, James H ^b  

^a Catalytic Longevity   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; CARNITINE; COCONUT OIL; HYDROXYCITRIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MEDIUM CHAIN TRIACYLGLYCEROL; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE RIBOSIDE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; RESVERATROL; SIRTUIN 1; SUCCINIC ACID; SUPEROXIDE; HIF1A PROTEIN, HUMAN; KETONE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; NEUROPROTECTIVE AGENT; SIRT1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BRAIN PROTECTION; CELL NUCLEUS; CYTOPLASM; DEGENERATIVE DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; ENZYME INHIBITION; FAT INTAKE; HIPPOCAMPUS; HUMAN; KETOGENESIS; KETOGENIC DIET; LOW CARBOHYDRATE DIET; MACROAUTOPHAGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PROTEIN ACETYLATION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERAPY EFFECT; UPREGULATION; ACETYLATION; ANIMAL; AUTOPHAGY; BRAIN; KETOACIDOSIS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACETYLATION; ANIMALS; AUTOPHAGY; BRAIN; HIPPOCAMPUS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KETOGENIC DIET; KETONES; KETOSIS; MULTIPROTEIN COMPLEXES; NEUROPROTECTIVE AGENTS; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 84946494246     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.08.002     Document Type: Article

References (176)

1. Gasior M., Rogawski M.A., Hartman A.L. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006 September, 17(5-6):431-439.
2. Maalouf M., Rho J.M., Mattson M.P. The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev 2009 March, 59(2):293-315.
3. Paoli A., Bianco A., Damiani E., Bosco G. Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed Res Int 2014, 2014:474296.
4. Puchowicz M.A., Zechel J.L., Valerio J., et al. Neuroprotection in diet-induced ketotic rat brain after focal ischemia. J Cereb Blood Flow Metab 2008 December, 28(12):1907-1916.
5. Xu K., Sun X., Eroku B.O., Tsipis C.P., Puchowicz M.A., LaManna J.C. Diet-induced ketosis improves cognitive performance in aged rats. Adv Exp Med Biol 2010, 662:71-75.
6. Fenselau A., Wallis K. Comparative studies on 3-oxo acid coenzyme A transferase from various rat tissues. Biochem J 1974 September, 142(3):619-627.
7. Selak M.A., Armour S.M., MacKenzie E.D., et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005 January, 7(1):77-85.
8. Koivunen P., Hirsila M., Remes A.M., Hassinen I.E., Kivirikko K.I., Myllyharju J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007 February 16, 282(7):4524-4532.
9. Semenza G.L. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007 October 9, 2007(407):cm8.
10. Puchowicz M.A., Xu K., Sun X., Ivy A., Emancipator D., LaManna J.C. Diet-induced ketosis increases capillary density without altered blood flow in rat brain. Am J Physiol Endocrinol Metab 2007 June, 292(6):E1607-E1615.
11. Ryall J.G., Dell'Orso S., Derfoul A., et al. The NAD(+)-dependent SIRT1 deacetylase translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells. Cell Stem Cell 2015 February 5, 16(2):171-183.
12. Maalouf M., Sullivan P.G., Davis L., Kim D.Y., Rho J.M. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 2007 March 2, 145(1):256-264.
13. Sullivan P.G., Rippy N.A., Dorenbos K., Concepcion R.C., Agarwal A.K., Rho J.M. The ketogenic diet increases mitochondrial uncoupling protein levels and activity. Ann Neurol 2004 April, 55(4):576-580.
14. Wang S.J., Zhao X.H., Chen W., et al. Sirtuin 1 activation enhances the PGC-1alpha/mitochondrial antioxidant system pathway in status epilepticus. Mol Med Rep 2015 January, 11(1):521-526.
15. Woyda-Ploszczyca A.M., Jarmuszkiewicz W. Different effects of guanine nucleotides (GDP and GTP) on protein-mediated mitochondrial proton leak. PLoS One 2014, 9(6):e98969.
16. Prince A., Zhang Y., Croniger C., Puchowicz M. Oxidative metabolism: glucose versus ketones. Adv Exp Med Biol 2013, 789:323-328.
17. Kim do Y., Abdelwahab M.G., Lee S.H., et al. Ketones prevent oxidative impairment of hippocampal synaptic integrity through KATP channels. PLoS One 2015, 10(4):e0119316.
18. Wang L., Zhu Q.L., Wang G.Z., et al. The protective roles of mitochondrial ATP-sensitive potassium channels during hypoxia-ischemia-reperfusion in brain. Neurosci Lett 2011 March 10, 491(1):63-67.
19. Busija D.W., Lacza Z., Rajapakse N., et al. Targeting mitochondrial ATP-sensitive potassium channels-a novel approach to neuroprotection. Brain Res Brain Res Rev 2004 November, 46(3):282-294.
20. Scheibye-Knudsen M., Mitchell S.J., Fang E.F., et al. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab 2014 November 4, 20(5):840-855.
21. Bough K.J., Wetherington J., Hassel B., et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006 August, 60(2):223-235.
22. Canto C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 2009 April, 20(2):98-105.
23. Tang B.L., Chua C.E. SIRT1 and neuronal diseases. Mol Aspects Med 2008 June, 29(3):187-200.
24. Srivastava S., Haigis M.C. Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer's and Parkinson's diseases. Curr Pharm Des 2011, 17(31):3418-3433.
25. Herskovits A.Z., Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron 2014 February 5, 81(3):471-483.
26. Wang R., Li J.J., Diao S., et al. Metabolic stress modulates Alzheimer's beta-secretase gene transcription via SIRT1-PPARgamma-PGC-1 in neurons. Cell Metab 2013 May 7, 17(5):685-694.
27. Min S.W., Cho S.H., Zhou Y., et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010 September 23, 67(6):953-966.
28. Cohen T.J., Guo J.L., Hurtado D.E., et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2011, 2:252.
29. Westerheide S.D., Anckar J., Stevens S.M., Sistonen L., Morimoto R.I. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 2009 February 20, 323(5917):1063-1066.
30. Zelin E., Freeman B.C. Lysine deacetylases regulate the heat shock response including the age-associated impairment of HSF1. J Mol Biol 2015 April 10, 427(7):1644-1654.
31. Hori Y.S., Kuno A., Hosoda R., Horio Y. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One 2013, 8(9):e73875.
32. Giannakou M.E., Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004 August, 14(8):408-412.
33. Sykes S.M., Mellert H.S., Holbert M.A., et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006 December 28, 24(6):841-851.
34. Kim J.H., Yoon E.K., Chung H.J., et al. P53 acetylation enhances taxol-induced apoptosis in human cancer cells. Apoptosis 2013 January, 18(1):110-120.
35. Lee I.H., Cao L., Mostoslavsky R., et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 2008 March 4, 105(9):3374-3379.
36. Kashiwaya Y., Bergman C., Lee J.H., et al. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging 2013 June, 34(6):1530-1539.
37. Brownlow M.L., Benner L., D'Agostino D., Gordon M.N., Morgan D. Ketogenic diet improves motor performance but not cognition in two mouse models of Alzheimer's pathology. PLoS One 2013, 8(9):e75713.
38. Gao J., Wang W.Y., Mao Y.W., et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010 August 26, 466(7310):1105-1109.
39. Zhao Y.N., Li W.F., Li F., et al. Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochem Biophys Res Commun 2013 June 14, 435(4):597-602.
40. Pan Y., Larson B., Araujo J.A., et al. Dietary supplementation with medium-chain TAG has long-lasting cognition-enhancing effects in aged dogs. Br J Nutr 2010 June, 103(12):1746-1754.
41. Reger M.A., Henderson S.T., Hale C., et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004 March, 25(3):311-314.
42. Sharma A., Bemis M., Desilets A.R. Role of medium chain triglycerides (Axona(R)) in the treatment of mild to moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 January 9.
43. Krikorian R., Shidler M.D., Dangelo K., Couch S.C., Benoit S.C., Clegg D.J. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol Aging 2012 February, 33(2):425-427.
44. Shimazu T., Hirschey M.D., Newman J., et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013 January 11, 339(6116):211-214.
45. Newman J.C., Verdin E. Ketone bodies as signaling metabolites. Trends Endocrinol Metab 2014 January, 25(1):42-52.
46. Coppede F. The potential of epigenetic therapies in neurodegenerative diseases. Front Genet 2014, 5:220.
47. Graff J., Rei D., Guan J.S., et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012 March 8, 483(7388):222-226.
48. Guan J.S., Haggarty S.J., Giacometti E., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009 May 7, 459(7243):55-60.
49. Wagner F.F., Zhang Y.L., Fass D.M., et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chem Sci 2015 January 1, 6(1):804-815.
50. Ricobaraza A., Cuadrado-Tejedor M., Marco S., Perez-Otano I., Garcia-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 2012 May, 22(5):1040-1050.
51. Cuadrado-Tejedor M., Ricobaraza A.L., Torrijo R., Franco R., Garcia-Osta A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer s disease-like phenotype of a commonly used mouse model. Curr Pharm Des 2013, 19(28):5076-5084.
52. Karagiannis T.C., Ververis K. Potential of chromatin modifying compounds for the treatment of Alzheimer's disease. Pathobiol Aging Age Relat Dis 2012, 2.
53. Harrison I.F., Dexter D.T. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?. Pharmacol Ther 2013 October, 140(1):34-52.
54. Kontopoulos E., Parvin J.D., Feany M.B. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006 October 15, 15(20):3012-3023.
55. Jin H., Kanthasamy A., Harischandra D.S., et al. Histone hyperacetylation up-regulates protein kinase Cdelta in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease. J Biol Chem 2014 December 12, 289(50):34743-34767.
56. Wu X., Chen P.S., Dallas S., et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 2008 December, 11(8):1123-1134.
57. Monti B., Gatta V., Piretti F., Raffaelli S.S., Virgili M., Contestabile A. Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. Neurotox Res 2010 February, 17(2):130-141.
58. Zhou W., Bercury K., Cummiskey J., Luong N., Lebin J., Freed C.R. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 2011 April 29, 286(17):14941-14951.
59. Kidd S.K., Schneider J.S. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011 October, 27(194):189-194.
60. Rane P., Shields J., Heffernan M., Guo Y., Akbarian S., King J.A. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 2012 June, 62(7):2409-2412.
61. St L.R., O'Brien L.M., Ahmad S.T. Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 2013 August, 29(246):382-390.
62. Zhu M., Li W.W., Lu C.Z. Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci Ther 2014 April, 20(4):308-316.
63. Collins L.M., Adriaanse L.J., Theratile S.D., Hegarty S.V., Sullivan A.M., O'Keeffe G.W. Class-IIa histone deacetylase inhibition promotes the growth of neural processes and protects them against neurotoxic insult. Mol Neurobiol 2014 July 29.
64. Sadri-Vakili G., Cha J.H. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res 2006 September, 3(4):403-408.
65. Gray S.G. Targeting Huntington's disease through histone deacetylases. Clin Epigenet 2011 August, 2(2):257-277.
66. McCampbell A., Taye A.A., Whitty L., Penney E., Steffan J.S., Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proc Natl Acad Sci U S A 2001 December 18, 98(26):15179-15184.
67. Ying M., Xu R., Wu X., et al. Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA. J Biol Chem 2006 May 5, 281(18):12580-12586.
68. Chou A.H., Chen S.Y., Yeh T.H., Weng Y.H., Wang H.L. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 2011 February, 41(2):481-488.
69. Ferrante R.J., Kubilus J.K., Lee J., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003 October 15, 23(28):9418-9427.
70. Jia H., Pallos J., Jacques V., et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 2012 May, 46(2):351-361.
71. Jia H., Kast R.J., Steffan J.S., Thomas E.A. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet 2012 December 15, 21(24):5280-5293.
72. Mielcarek M., Landles C., Weiss A., et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 2013 November, 11(11):e1001717.
73. Abdel-Magid A.F. Histone deacetylase 4 (HDAC4) inhibitors: a promising treatment for Huntington's disease. ACS Med Chem Lett 2013 August 8, 4(8):692-693.
74. Ryu H., Smith K., Camelo S.I., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005 June, 93(5):1087-1098.
75. Cudkowicz M.E., Andres P.L., Macdonald S.A., et al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 2009 April, 10(2):99-106.
76. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008 October, 7(10):854-868.
77. Rai M., Soragni E., Jenssen K., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008, 3(4):e1958.
78. Saiyed Z.M., Gandhi N., Agudelo M., et al. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int 2011 May, 58(6):656-664.
79. McDaniel S.S., Rensing N.R., Thio L.L., Yamada K.A., Wong M. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia 2011 March, 52(3):e7-e11.
80. Guo W., Qian L., Zhang J., et al. Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J Neurosci Res 2011 November, 89(11):1723-1736.
81. Zhang H., Bosch-Marce M., Shimoda L.A., et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008 April 18, 283(16):10892-10903.
82. Bellot G., Garcia-Medina R., Gounon P., et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009 May, 29(10):2570-2581.
83. Jeong J.K., Moon M.H., Lee Y.J., Seol J.W., Park S.Y. Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity. Neurobiol Aging 2013 January, 34(1):146-156.
84. Shin B.H., Lim Y., Oh H.J., et al. Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy. PLoS One 2013, 8(6):e64953.
85. Ng F., Tang B.L. Sirtuins' modulation of autophagy. J Cell Physiol 2013 December, 228(12):2262-2270.
86. Hosokawa N., Hara T., Kaizuka T., et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009 April, 20(7):1981-1991.
87. Egan D., Kim J., Shaw R.J., Guan K.L. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy 2011 June, 7(6):643-644.
88. Alirezaei M., Kemball C.C., Flynn C.T., Wood M.R., Whitton J.L., Kiosses W.B. Short-term fasting induces profound neuronal autophagy. Autophagy 2010 August, 6(6):702-710.
89. Alirezaei M., Kemball C.C., Whitton J.L. Autophagy, inflammation and neurodegenerative disease. Eur J Neurosci 2011 January, 33(2):197-204.
90. Hoffman W.H., Shacka J.J., Andjelkovic A.V. Autophagy in the brains of young patients with poorly controlled T1DM and fatal diabetic ketoacidosis. Exp Mol Pathol 2012 October, 93(2):273-280.
91. Yue Z., Friedman L., Komatsu M., Tanaka K. The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases. Biochim Biophys Acta 2009 September, 1793(9):1496-1507.
92. Komatsu M., Ueno T., Waguri S., Uchiyama Y., Kominami E., Tanaka K. Constitutive autophagy: vital role in clearance of unfavorable proteins in neurons. Cell Death Differ 2007 May, 14(5):887-894.
93. Banerjee R., Beal M.F., Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends Neurosci 2010 December, 33(12):541-549.
94. Wu Y., Li X., Zhu J.X., et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 2011, 19(3):163-174.
95. Pan T., Rawal P., Wu Y., Xie W., Jankovic J., Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 2009 December 1, 164(2):541-551.
96. Majumder S., Richardson A., Strong R., Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 2011, 6(9):e25416.
97. Yang D.S., Stavrides P., Mohan P.S., et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy 2011 July, 7(7):788-789.
98. Tian Y., Bustos V., Flajolet M., Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J 2011 June, 25(6):1934-1942.
99. Li L., Zhang X., Le W. Autophagy dysfunction in Alzheimer's disease. Neurodegener Dis 2010, 7(4):265-271.
100. Spilman P., Podlutskaya N., Hart M.J., et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010, 5(4):e9979.
101. Vingtdeux V., Giliberto L., Zhao H., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem 2010 March 19, 285(12):9100-9113.
102. Roscic A., Baldo B., Crochemore C., Marcellin D., Paganetti P. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J Neurochem 2011 October, 119(2):398-407.
103. Garcia-Arencibia M., Hochfeld W.E., Toh P.P., Rubinsztein D.C. Autophagy, a guardian against neurodegeneration. Semin Cell Dev Biol 2010 September, 21(7):691-698.
104. Wu J.J., Quijano C., Chen E., et al. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging (Albany NY) 2009 April, 1(4):425-437.
105. Natarajan R., Salloum F.N., Fisher B.J., Smithson L., Almenara J., Fowler A.A. Prolyl hydroxylase inhibition attenuates post-ischemic cardiac injury via induction of endoplasmic reticulum stress genes. Vasc Pharmacol 2009 August, 51(2-3):110-118.
106. Kupershmidt L., Weinreb O., Amit T., Mandel S., Carri M.T., Youdim M.B. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2009 November, 23(11):3766-3779.
107. Niatsetskaya Z., Basso M., Speer R.E., et al. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 2010 April, 12(4):435-443.
108. Avramovich-Tirosh Y., Bar-Am O., Amit T., Youdim M.B., Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res 2010 June, 7(4):300-306.
109. Lee D.W., Rajagopalan S., Siddiq A., et al. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem 2009 October 16, 284(42):29065-29076.
110. Wu Y., Li X., Xie W., Jankovic J., Le W., Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int 2010 October, 57(3):198-205.
111. Lee J.W., Park S., Takahashi Y., Wang H.G. The association of AMPK with ULK1 regulates autophagy. PLoS One 2010, 5(11):e15394.
112. Roach P.J. AMPK→ULK1→autophagy. Mol Cell Biol 2011 August, 31(15):3082-3084.
113. Zhou G., Myers R., Li Y., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001 October, 108(8):1167-1174.
114. Musi N., Hirshman M.F., Nygren J., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002 July, 51(7):2074-2081.
115. Labuzek K., Suchy D., Gabryel B., Bielecka A., Liber S., Okopien B. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010 September, 62(5):956-965.
116. Lee Y.S., Kim W.S., Kim K.H., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006 August, 55(8):2256-2264.
117. Turner N., Li J.Y., Gosby A., et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008 May, 57(5):1414-1418.
118. Kulkarni S.K., Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010 March, 24(3):317-324.
119. Um J.H., Park S.J., Kang H., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010 March, 59(3):554-563.
120. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004 December, 32(12):1377-1382.
121. Boocock D.J., Faust G.E., Patel K.R., et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007 June, 16(6):1246-1252.
122. Fulco M., Cen Y., Zhao P., et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008 May, 14(5):661-673.
123. Brandauer J., Vienberg S.G., Andersen M.A., et al. AMP-activated protein kinase regulates nicotinamide phosphoribosyl transferase expression in skeletal muscle. J Physiol 2013 October 15, 591(Pt 20):5207-5220.
124. Lan F., Cacicedo J.M., Ruderman N., Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 2008 October 10, 283(41):27628-27635.
125. Li J., Benashski S.E., Venna V.R., McCullough L.D. Effects of metformin in experimental stroke. Stroke 2010 November, 41(11):2645-2652.
126. Finn P.F., Dice J.F. Ketone bodies stimulate chaperone-mediated autophagy. J Biol Chem 2005 July 8, 280(27):25864-25870.
127. Chi Y., Sauve A.A. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care 2013 November, 16(6):657-661.
128. Gong B., Pan Y., Vempati P., et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013 June, 34(6):1581-1588.
129. Rahman M., Muhammad S., Khan M.A., et al. The beta-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages. Nat Commun 2014, 5:3944.
130. Fu S.P., Wang J.F., Xue W.J., et al. Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson inverted question marks disease models are mediated by GPR109A-dependent mechanisms. J Neuroinflammation 2015 January 17, 12(1):9.
131. Mayorek N., Bar-Tana J. Medium chain fatty acids as specific substrates for diglyceride acyltransferase in cultured hepatocytes. J Biol Chem 1983 June 10, 258(11):6789-6792.
132. Hoppel C.L. Carnitine and carnitine palmitoyltransferase in fatty acid oxidation and ketosis. Fed Proc 1982 October, 41(12):2853-2857.
133. Liu Y.M. Medium-chain triglyceride (MCT) ketogenic therapy. Epilepsia 2008 November, 49(Suppl. 8):33-36.
134. Nunes P.A., Pires-Cabral P., Ferreira-Dias S. Production of olive oil enriched with medium chain fatty acids catalysed by commercial immobilised lipases. Food Chem 2011 August 1, 127(3):993-998.
135. Seaton T.B., Welle S.L., Warenko M.K., Campbell R.G. Thermic effect of medium-chain and long-chain triglycerides in man. Am J Clin Nutr 1986 November, 44(5):630-634.
136. Courchesne-Loyer A., Fortier M., Tremblay-Mercier J., et al. Stimulation of mild, sustained ketonemia by medium-chain triacylglycerols in healthy humans: estimated potential contribution to brain energy metabolism. Nutrition 2013 April, 29(4):635-640.
137. Hegardt F.G. Mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase: a control enzyme in ketogenesis. Biochem J 1999 March 15, 338(Pt. 3):569-582.
138. Clarke K., Tchabanenko K., Pawlosky R., et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol 2012 August, 63(3):401-408.
139. Newport M.T., VanItallie T.B., Kashiwaya Y., King M.T., Veech R.L. A new way to produce hyperketonemia: use of ketone ester in a case of Alzheimer's disease. Alzheimers Dement 2015 January, 11(1):99-103.
140. Marsh E.B., Freeman J.M., Kossoff E.H., et al. The outcome of children with intractable seizures: a 3- to 6-year follow-up of 67 children who remained on the ketogenic diet less than one year. Epilepsia 2006 February, 47(2):425-430.
141. Patel A., Pyzik P.L., Turner Z., Rubenstein J.E., Kossoff E.H. Long-term outcomes of children treated with the ketogenic diet in the past. Epilepsia 2010 July, 51(7):1277-1282.
142. Fung T.T., van Dam R.M., Hankinson S.E., Stampfer M., Willett W.C., Hu F.B. Low-carbohydrate diets and all-cause and cause-specific mortality: two cohort studies. Ann Intern Med 2010 September 7, 153(5):289-298.
143. Jenkins D.J., Wong J.M., Kendall C.W., et al. The effect of a plant-based low-carbohydrate ("Eco-Atkins") diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med 2009 June 8, 169(11):1046-1054.
144. Tuttle K.R., Milton J.E. The "Eco-Atkins" diet: new twist on an old tale. Arch Intern Med 2009 June 8, 169(11):1027.
145. Perez-Guisado J., Munoz-Serrano A. A pilot study of the Spanish Ketogenic Mediterranean Diet: an effective therapy for the metabolic syndrome. J Med Food 2011 July, 14(7-8):681-687.
146. Paoli A., Bianco A., Grimaldi K.A., Lodi A., Bosco G. Long term successful weight loss with a combination biphasic ketogenic Mediterranean diet and Mediterranean diet maintenance protocol. Nutrients 2013 December, 5(12):5205-5217.
147. Fuehrlein B.S., Rutenberg M.S., Silver J.N., et al. Differential metabolic effects of saturated versus polyunsaturated fats in ketogenic diets. J Clin Endocrinol Metab 2004 April, 89(4):1641-1645.
148. Valdearcos M., Robblee M.M., Benjamin D.I., Nomura D.K., Xu A.W., Koliwad S.K. Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function. Cell Rep 2014 December 24, 9(6):2124-2138.
149. Milanski M., Degasperi G., Coope A., et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 2009 January 14, 29(2):359-370.
150. Psaltopoulou T., Sergentanis T.N., Panagiotakos D.B., Sergentanis I.N., Kosti R., Scarmeas N. Mediterranean diet, stroke, cognitive impairment, and depression: a meta-analysis. Ann Neurol 2013 October, 74(4):580-591.
151. Singh B., Parsaik A.K., Mielke M.M., et al. Association of mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 2014, 39(2):271-282.
152. Solfrizzi V., Panza F. Mediterranean diet and cognitive decline. A lesson from the whole-diet approach: what challenges lie ahead?. J Alzheimers Dis 2014, 39(2):283-286.
153. Gao X., Chen H., Fung T.T., et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007 November, 86(5):1486-1494.
154. Alcalay R.N., Gu Y., Mejia-Santana H., Cote L., Marder K.S., Scarmeas N. The association between Mediterranean diet adherence and Parkinson's disease. Mov Disord 2012 May, 27(6):771-774.
155. Barnard N.D., Bunner A.E., Agarwal U. Saturated and trans fats and dementia: a systematic review. Neurobiol Aging 2014 September, 35(Suppl. 2):S65-S73.
156. Kielb S., Koo H.P., Bloom D.A., Faerber G.J. Nephrolithiasis associated with the ketogenic diet. J Urol 2000 August, 164(2):464-466.
157. Sampath A., Kossoff E.H., Furth S.L., Pyzik P.L., Vining E.P. Kidney stones and the ketogenic diet: risk factors and prevention. J Child Neurol 2007 April, 22(4):375-378.
158. Bergqvist A.G., Schall J.I., Stallings V.A., Zemel B.S. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet. Am J Clin Nutr 2008 December, 88(6):1678-1684.
159. McNally M.A., Pyzik P.L., Rubenstein J.E., Hamdy R.F., Kossoff E.H. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics 2009 August, 124(2):e300-e304.
160. Frassetto L., Morris R.C., Sebastian A. Long-term persistence of the urine calcium-lowering effect of potassium bicarbonate in postmenopausal women. J Clin Endocrinol Metab 2005 February, 90(2):831-834.
161. White A.M., Johnston C.S., Swan P.D., Tjonn S.L., Sears B. Blood ketones are directly related to fatigue and perceived effort during exercise in overweight adults adhering to low-carbohydrate diets for weight loss: a pilot study. J Am Diet Assoc 2007 October, 107(10):1792-1796.
162. McCarty M.F. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Med Hypotheses 1994 April, 42(4):215-225.
163. McGarry J.D., Robles-Valdes C., Foster D.W. Role of carnitine in hepatic ketogenesis. Proc Natl Acad Sci U S A 1975 November, 72(11):4385-4388.
164. McCarty M.F. Orthomolecular aids for dieting. Med Hypotheses 1982 March, 8(3):269-274.
165. McGarry J.D., Leatherman G.F., Foster D.W. Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. J Biol Chem 1978 June 25, 253(12):4128-4136.
166. Hamilton J.G., Sullivan A.C., Kritchevsky D. Hupolipidemic activity of (-)-hydroxycitrate. Lipids 1977 January, 12(1):1-9.
167. Kim Y.D., Park K.G., Lee Y.S., et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008 February, 57(2):306-314.
168. Brusq J.M., Ancellin N., Grondin P., et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006 June, 47(6):1281-1288.
169. Saha A.K., Ruderman N.B. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem 2003 November, 253(1-2):65-70.
170. McGarry J., Wright P.H., Foster D.W. Hormonal control of ketogenesis. Rapid activation of hepatic ketogenic capacity in fed rats by anti-insulin serum and glucagon. J Clin Invest 1975 June, 55(6):1202-1209.
171. Park E.A., Mynatt R.L., Cook G.A., Kashfi K. Insulin regulates enzyme activity, malonyl-CoA sensitivity and mRNA abundance of hepatic carnitine palmitoyltransferase-I. Biochem J 1995 September 15, 310(Pt 3):853-858.
172. Pegorier J.P., Garcia-Garcia M.V., Prip-Buus C., Duee P.H., Kohl C., Girard J. Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses. Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment. Biochem J 1989 November 15, 264(1):93-100.
173. Johnson R.H., Walton J.L., Krebs H.A., Williamson D.H. Post-exercise ketosis. Lancet 1969 December 27, 2(7635):1383-1385.
174. Koeslag J.H., Noakes T.D., Sloan A.W. Post-exercise ketosis. J Physiol 1980 April, 301:79-90.
175. McCarty M.F., Falahati-Nini A. Neuroprotective potential of the Bahadori leanness program: a "mini-fast with exercise" strategy. Med Hypotheses 2007, 68(5):935-940.
176. Bahadori B., McCarty M.F., Barroso-Aranda J., Gustin J.C., Contreras F. A "mini-fast with exercise" protocol for fat loss. Med Hypotheses 2009 October, 73(4):619-622.